Home > Reports, Tools, & Publications > Outpatient Nirmatrelvir-Ritonavir and Remdesivir in Canada

Outpatient Nirmatrelvir-Ritonavir and Remdesivir in Canada

J. Michael Paterson, Colin Dormuth, Donica Janzen, Alan Katz, Paul Ronksley, Sylvia Aponte-Hao, Matt Dahl, Tayler Dawn-Scory, Houssem Missaoui, Xinya Lu, Jean-Luc Kabore, Mike Benigeri, Audray St-Jean, Ruby Sheng, Fangyun Wu
Canada's Drug Agency
May 3, 2024

The publication aims to determine the outpatient utilization of nirmatrelvir-ritonavir and remdesivir in Canada.

Citation

Paterson, J.M., Dormuth, C., Janzen, D., Katz, A., Ronksley, P., Aponte-Hao, S., Dahl, M., Dawn-Scory,T., Missaoui, H., Lu, X., et al. Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada.(2024) https://www.cda-amc.ca/outpatient-nirmatrelvir-ritonavir-and-remdesivir-utilization-canada

https://www.cda-amc.ca/outpatient-nirmatrelvir-ritonavir-and-remdesivir-utilization-canada